Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

105.38 -1.49 (-1.39%)
Official Closing Price Updated: 7:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Will This Billion-Dollar Acquisition Be a Smart Move for Merck?
Merck recently completed its acquisition of a California-based biotech company. 
Via The Motley Fool
The 3 Best Biotech Stocks Under $1 to Buy for January
Even the best small biotech stocks can go bust on a single bad study, but the winners can make their early investors rich. 
Via InvestorPlace
2 Market-Beating Stocks to Buy in 2023 and Hold for 10 Years
These two healthcare giants defied the bear market last year. 
Via The Motley Fool
How I'd Invest $50,000 for Retirement If I Had to Start From Scratch
Starting with a completely clean slate free of the usual investment baggage is a liberating, insightful exercise. 
Via The Motley Fool
Earn Dividends Every Month With These 3 Stocks
Having this trio of high-quality companies in your portfolio will ensure that you collect a payout each month. 
Via The Motley Fool
Where Merck & Co Stands With Analysts
 
Via Benzinga
Why Did Veeva Systems Stock Fall 15% in December?
Investors were disappointed by Veeva's growth and profit forecasts. 
Via The Motley Fool
Analyst Ratings for Merck & Co
 
Via Benzinga
My Biggest Winners Of 2022
Wondering which of my investments did the best in 2022, and how I feel about them today. Check out the video for full details. 
Via Talk Markets
Want to Collect a Dividend Every Month? Buy These 3 High-Yielding Stocks
You can keep the cash flowing into your portfolio with these above-average payouts. 
Via The Motley Fool
This Dow Jones Stock Crushed the Market in 2022 -- Can It Do It Again?
This pharmaceutical was the second-best performing Dow Jones stock in 2022 behind the energy giant Chevron. 
Via The Motley Fool
Seagen's Tukysa Becomes First FDA-Approved Treatment For HER2-Positive Metastatic Colorectal Cancer
 
Via Benzinga
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem. 
Via Benzinga
Can Cannabinoid CB2 Receptor Antagonist Combined With KEYTRUDA Be Effective In Patients With Advanced Solid Tumors? These Two Companies Aim To Find Out
Teon Therapeutics a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and development of G-Protein Coupled Receptor immuno-oncology therapies in difficult-to-treat... 
Via Benzinga
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing. 
Via Talk Markets
Novocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Grace
Shares have given back a chunk of their 69% single-day gain on a lung cancer study. 
Via Investor's Business Daily
3 Top Stocks to Buy for the Long Haul
Not too many companies are built not just to last, but to thrive in any and all market environments. 
Via The Motley Fool
Johnson & Johnson Cuts Production, Ends Contracts For Not So Successful COVID-19 Shot
Johnson & Johnson (NYSE: JNJ) has significantly scaled back its efforts of manufacturing its COVID-19 vaccine after facing a fall in demand. 
Via Benzinga
FAA Technology Glitch Hits US Flights Operations, Coca-Cola & PepsiCo Under FTC Probe, Rivian Hit By Mass Executive Exodus: Today's Top Stories
Reuters 
Via Benzinga
Merck, Pfizer Rebuts China's Request For Further Price Cuts For COVID-19 Drugs
Merck & Co Inc (NYSE: MRK) and Pfizer Inc (NYSE: PFE) have reportedly signaled that they have not agreed to a request by the Chinese authorities for deeper price cuts for COVID-19 treatments. 
Via Benzinga
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns. 
Via Talk Markets
7 Hot Healthcare Stocks to Watch in 2023
Strong earnings and robust dividend payments make healthcare stocks attractive during times of uncertainty and volatility. 
Via InvestorPlace
5 Top Pharma Stocks of 2022 to Buy for the Long Haul
The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Merck has a number of efforts in the works to help avoid a Keytruda generics pitfall. 
Via Investor's Business Daily
Merck Vs. Pfizer: Why Analyst Upgrades One Pharmaceutical Stock, While Downgrading Another
The health care sector held up relatively well in a difficult year for stocks in 2022. On Wednesday, one analyst adjusted his coverage of two large cap pharmaceutical stocks heading into what could be... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
3 Top Stocks of 2022 That Will Shine Again in 2023
The S&P 500 had its worst year since 2008. Of the 143 stocks that gained this past year, these three top stocks of 2022 could do it again. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
43 44 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.